Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological Malignancy and Solid Tumor Development.
CD74 (HLA-DR-associated invariant chain) features a thyroglobulin type-1 domain (UniProt P04233) and is a rapidly internalizing transmembrane protein, making it an ideal target for ADCs and bispecifics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD74 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD74 ECD-Fc / Mutant Protein (p33 isoform) High purity (>95%), Endotoxin <1EU/µg, Sequence Verified. HEK293 expressed for native glycosylation. |
View CD74 Products |
| Gene Delivery | CD74 Full-Length ORF / Lentivirus Full-length ORF for stable cell lines (CHO/HEK293). Critical for conformational internalization assays. |
View CD74 Products |
| Benchmark Ab | Anti-CD74 (Sequence of Milatuzumab) Recombinant positive control for binding and blocking studies. |
View CD74 Products |
| Validator | CD74 siRNA Set (3 unique sequences) For knockdown specificity verification in functional assays. |
View CD74 Products |
| Related Target A | MIF (Macrophage Migration Inhibitory Factor) Primary natural ligand for CD74, crucial for tumor microenvironment signaling. |
View MIF Products |
| Related Target B | HLA-DRA MHC Class II chaperone partner, essential for antigen presentation studies. |
View HLA-DRA Products |
| Related Target C | CXCR4 Co-receptor with CD74 for MIF signal transduction. Relevant for combination therapy screening. |
View CXCR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Rapid Internalization Validation for ADCs | HEK293 Expressed (Native Glycosylation) ECD-Fc enabling precise endocytosis tracking; lentivirus stable cell lines for pH-sensitive dye uptake assays. |
| Cross-species Preclinical Toxicity Eval | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and verified sequence identity. |
| Isoform Selectivity (p33 vs p41) | Distinct recombinant proteins for p33 and p41 isoforms, enabling precise epitope mapping. |
| Lack of Reliable Controls | Sequence-verified clinical benchmark antibodies (Milatuzumab biosimilar) included for assay baseline. |
| Specificity Control | CD74 siRNA for target-specific signal reduction in binding assays. |
Live CD74 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research (ADC)
- ➤ General Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for CD74 therapeutics is intensifying, with major players shifting focus from traditional naked mAbs to Antibody-Drug Conjugates (ADCs) and bispecifics. As first-generation therapies like STRO-001 (Sutro Biopharma) advance through Phase I/II for Non-Hodgkin's Lymphoma and Multiple Myeloma, the next wave of R&D is targeting solid tumor indications (pancreatic, gastric) and exploring combinations with CD47 or CD20 blockades. Because CD74 is highly expressed on B-cell malignancies and rapidly internalizes, it represents an ideal payload-delivery conduit. The restricted expression on normal tissues (primarily B cells and APCs) offers a favorable therapeutic window. Future directions include optimizing payload release mechanisms within the acidic endosomal environment, and developing bispecific antibodies that engage CD74 and CD47 for enhanced tumor killing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Sutro Biopharma (STRO-001), Pfizer/Seagen | NHL, Multiple Myeloma, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc & Lentivirus stable cell lines) |
| Naked mAb | Immunomedics / Gilead (Milatuzumab) | CLL, SLE, NHL | Direct Binding Affinity (Need sequence-verified ECD for SPR) |
| Bispecific | Various Preclinical | B-cell Malignancies | Heterodimer Validation (Need cross-reactive Abs & HLA-DR complexes) |
| Radioimmunoconjugate | Academic / Imaging Consortia | Diagnostic Imaging | Specificity Verification (Need siRNA controls) |
Assay Strategy Recommendations for Best-in-Class Drug Development
To differentiate CD74-targeting drugs, the following assay strategies are essential:
- Internalization Kinetics: Use pH-sensitive dye (pHrodo) with lentivirus-generated stable cell lines to measure endocytosis rates and lysosomal trafficking.
- Epitope Binning & MIF Blocking: Use SPR/Octet to map epitopes relative to Milatuzumab; assess blockade of MIF-CD74 interaction to reverse immunosuppression.
- Cross-Species Reactivity: Test binding to human, cynomolgus, and mouse CD74 ECD-Fc proteins to ensure translational relevance of toxicology studies.
- Isoform Selectivity: Evaluate binding to p33 vs p41 isoforms; p41 contains the Ii-key fragment that may influence antibody binding.
The TarMart product line directly supports each of these assays with high-purity proteins, lentiviral constructs, and benchmark antibodies.